NCT01548235View on ClinicalTrials.gov

Observational Safety Study in Subjects With Type 2 Diabetes Mellitus Starting or Switching to Biphasic Insulin Aspart 30 Treatment

CompletedOBSERVATIONAL
Enrollment

423

Participants

Timeline

Start Date

February 28, 2006

Primary Completion Date

April 30, 2007

Study Completion Date

April 30, 2007

Conditions
DiabetesDiabetes Mellitus, Type 2
Interventions
DRUG

biphasic insulin aspart 30

Prescribed biphasic insulin aspart 30 as part of routine care. Starting dose, dose titration and injection frequency determined individually by each physician.

Trial Locations (1)

2300

Novo Nordisk Investigational Site, Copenhagen S

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY

NCT01548235 - Observational Safety Study in Subjects With Type 2 Diabetes Mellitus Starting or Switching to Biphasic Insulin Aspart 30 Treatment | Biotech Hunter | Biotech Hunter